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ABSTRACT 
The scientific evidence to support the value of a range of non-pharmacological interventions 
for people with Parkinson’s disease (PD) is increasing. However, showing unequivocally that 
specific interventions are better than usual care is not straightforward because of generic 
drawbacks of clinical trials. Here, we address these challenges, specifically related to the 
context of evaluating complex non-pharmacological interventions for people with PD. 
Moreover, we discuss the potential merits of undertaking “real world” analyses using 
medical claims data. We illustrate this approach by discussing an interesting recent 
publication in The Lancet Neurology, which used such an approach to demonstrate the value 
of specialized physiotherapy for PD patients, over and above usual care physiotherapy. 
 
BACKGROUND 
It is increasingly being recognized that Parkinson’s disease (PD), given its range of problems, 
is managed best using a multidisciplinary approach.[1, 2] Such a team approach should 
include not only conventional medical interventions (pharmacotherapy and deep brain 
stimulation), but also a range of non-pharmacological approaches including, but not limited 
to, physiotherapy, occupational therapy and speech-language therapy. The perception that 
such non-pharmacological interventions have added value for people with PD was, at least 
initially, based largely on theoretical rationale and anecdotal evidence. An exponential 
increase in randomized controlled trials and systematic reviews now provides high-quality 
scientific evidence to support the merits of a range of non-pharmacological interventions for 
people with PD. 
 
However, to unequivocally demonstrate that specific non-pharmacological interventions are 
better than usual care is not an easy task. This is related in part to the generic drawbacks of 
clinical trials, which become even more apparent when evaluating complex healthcare 
interventions such as physiotherapy or multidisciplinary interventions. Here, we briefly 
address these generic challenges, and discuss them in the context of evaluating non-
pharmacological interventions for people with PD. We then consider a complementary 
approach, which is based on an analysis of medical claims data, with particular reference to 
a recent publication in The Lancet Neurology.[3] We conclude by highlighting the broader 
implications of this approach, and how this and other methodological approaches might help 
to shape the future of care for neurological patients. 
 
THE CHALLENGES OF CLINICAL TRIALS 
The randomized controlled trial (RCT) remains the gold standard for evaluating new 
healthcare interventions and is a powerful approach to evaluate effectiveness.[4] Clear 
advantages include the rigorous measures that are taken to avoid bias and to control for 
influences of confounding factors by means of a concealed randomization procedure. 
However, the design of RCTs is also subject to a number of limitations.[5] 
 
First, the population included in a RCT is typically selected using strict inclusion/exclusion 
criteria, which by definition means that the study results cannot be generalized to a real-life 
population. Recent pragmatic RCTs are to be commended for having used broader in- and 
exclusion criteria,[6, 7] but some populations are still structurally over- or underrepresented 
in other studies on PD. For example, most patients with PD are older adults with multiple co-
morbid conditions, but RCTs usually exclude such co-morbid patients, and consist largely of 
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younger patients. Therefore, we do not know whether evidence-based treatments are also 
effective in a real-life and more vulnerable population of PD patients.[8] Patients with 
cognitive decline are also often excluded from trials; this exclusion can be problematic when 
the outcome is related in part to cognitive functional capacity. For example, an analysis in 
this journal showed that fall intervention studies typically do not include patients with 
cognitive decline, yet falls are clearly related to the presence of frontal executive deficits.[9] 
Patients at the extremes of the age spectrum are often also excluded from trials, even 
though both treatment effects and adverse events may well be different for very young or 
very old patients. Underrepresentation of older adults with PD, who represent the majority 
of the PD population, from clinical trials is particularly evident. The effect of these commonly 
applied inclusion/exclusion criteria is that patients with mild disease are preferentially 
included in trials, so the results cannot be generalized to those with more advanced disease. 
Finally, we recently showed that men are significantly overrepresented in RCTs (even 
accounting for the slighter higher incidence of PD in men compared to women), with the 
proportion of men being extra high in more complex or technically oriented studies 
(Tosserams et al., submitted). Studies of non-pharmacological interventions are certainly no 
exception, and in fact seem particularly plagued by these recruitment challenges.[10, 11] For 
example, a recent RCT showed that treadmill walking combined with virtual reality 
immersion helped to reduce falls in PD patients.[12] However, our own center (which 
participated in this study) faced serious recruitment issues because the intervention was 
hospital-based, and many patients refused participation because the time and energy 
needed for multiple weekly visits to the hospital was perceived as too cumbersome. 
 
Second, since RCTs are very costly and time-consuming, most studies include only a 
relatively small sample size, and follow their participants for only a limited period. A recent 
review showed that this issue also applies to the field of non-pharmacological interventions, 
where the majority of RCTs included only between 20 and 100 patients (mean=80).[13] The 
largest study included 586 patients, but many others appeared to be underpowered. 
Moreover, these studies followed their patients for only short periods of time, with a median 
of only 16 weeks.[13] In exceptional cases, a two-year follow-up period was reached, so the 
long-term effects remain unknown for virtually all non-pharmacological interventions. 
 
Third, many studies of non-pharmacological interventions are troubled by rather high 
numbers of patients who are lost to follow-up. For example, a recent review showed a great 
variability in attrition rates, between 10% up to 80% in studies on vocal rehabilitation.[14] 
These high attrition rates introduce bias to the results of any study. We should point out that 
loss to follow-up is a problem for any study design, and RCTs actually perform reasonably 
well here by comparison to other clinical studies 
 
Finally, after successfully completing an RCT, it often proves difficult to implement new 
interventions into everyday clinical practice. In fact, also replication of study results is 
difficult, where initial stronger results as well as contradictions are reported.[15] This issue is 
potentially particularly vexing for non-pharmacological interventions, which in the clinical 
trial setting are administered typically by well-trained and highly motivated personnel 
(‘selection bias of therapists’). It is possible that the positive experiences with e.g. dance 
therapy are explained at least in part by the enthusiasm and dedication of the dance trainers 
in those studies.[16] It is not necessarily feasible to engage similarly motivated and equally 
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skilled personnel to now deliver these interventions in daily practice outside the original 
study centers, and this may have a detrimental  effect on the therapy being administered.  
 
WHAT ANALYSES OF MEDICAL CLAIMS CAN OFFER 
Mining medical claims databases, on the other hand, offers a potential solution for at least 
some of these drawbacks. This includes the opportunity to include very large numbers of 
patients that can potentially be followed for long periods of time without attrition. 
Moreover, medical claims data are more likely to reflect healthcare in real-life clinical 
practice, including access to a much more representative population across all ages, disease 
severities and co-morbid conditions. By definition, medical claims data contain information 
about medical expenses, enabling evaluations of cost-effectiveness after a real-life 
implementation of an intervention, especially when being linked to other databases, for 
example clinical outcome registries. Studying a medical claims database is also much 
cheaper than performing a clinical trial, because data collection has already taken place as 
part of regular healthcare, so only the personnel for data analyses has to be funded.[17] 
Research has shown that PD patients can be identified reliably in medical claims data using a 
combination of PD claim factors.[17] Table 1 offers an overview of studies that used medical 
claims in the field of PD. 
 
However, this approach also has challenges of its own. The first drawback relates to the lack 
of direct information on disease-specific patient characteristics. Simple demographics such 
as age and gender are available, but detailed information about disease status is normally 
lacking (e.g. MDS-UPDRS scores). Therefore, comparability between groups who either did 
or did not receive a particular intervention on disease-specific measures cannot be 
guaranteed. A second drawback is that group separation is not based on randomization, and 
therefore potentially subject to all sorts of bias. For example, it is theoretically possible to 
mine medical claims data to search for differences in outcome between patients who 
received multidisciplinary care, versus those who did not. However, it is quite possible that 
patients with e.g. greater disease severity or those with higher education were preferentially 
referred to such interventions, leading to baseline differences that could explain differences 
in outcome. Third, it is impossible to be certain which intervention was ultimately 
responsible for the results, because patients in everyday clinical practice may receive a 
broad range of treatments, all of which can contribute to a different outcome. Moreover, 
coupled to this, there may be changes in social circumstances which are not captured in such 
databases. Without carefully controlling for each of them (which is a strength of RCTs), it is 
impossible to pinpoint a particular treatment as being the most effective ingredient. Fourth, 
medical claims databases also have to deal with attrition. In the Netherlands, this attrition 
rate is limited because of some national regulatory rules (i.e. health insurance is obligatory 
for every citizen, insurers have nationwide coverage, and changing from one insurer to 
another is only allowed at the beginning of each new year). The percentage of people 
switching their health insurance in the Netherlands (mostly young, healthy individuals) was 
6.8% in 2016 and 6.3% in 2017.[18, 19], which is comparable to other European countries 
(i.e. Germany and Switzerland) and higher than for example Belgium and Israel where only 
1% switches insurer.[20] However, also in other medical claims databases where loss to 
follow-up is higher compared to the Dutch situation, attrition is usually not the main concern 
because these rates in general do not reach 20% (which is often used as the cut-off for 
introducing bias[21]). Fifth, the quality of the data in medical claims databases (e.g. 
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reliability, validity, sensitivity) is often unknown, and sometimes even known to be 
insufficient.[22] A particular concern is the presence of measurement error, which refers to 
the fact that in medical claims, conditions are defined imprecisely and inaccurately 
(specifically, it is uncertain how well general neurologists follow accepted international 
criteria to diagnose PD), that measurement may vary in a biased way, and that little is known 
about how robust the measures are. For example, the number of claims is often not identical 
to the number of unique visits[23] and some treatments or components of treatments may 
either not be claimed or wrongly coded.[24] Augmenting medical claims databases with 
other data sources, for example with prospective, longitudinal registries, may offer a 
potential solution for this.[22] Finally, just as in RCTs, researchers who analyze medical 
claims must define a primary outcome at the outset, prior to performing the analyses. The 
number of possible outcomes in a medical claims database is almost infinite, creating a risk 
of spurious findings unless a predefined primary outcome is decided upon before embarking 
upon the analyses. 
 
Importantly, in light of these challenges, we do not see this approach as a substitute for well-
designed trials, but rather as a complementary method to gather converging evidence to 
help in the design or interpretation of findings in a RCT. Indeed, medical claims data are 
increasingly being recognized and used as a valuable source of scientific information, next to 
the more traditional research methods in medical science.[25]  
 
RCTs and analyses of medical claims databases can be seen as two extremes of a spectrum 
of study methodologies. However, there are also other methodological options along this 
spectrum that can be used to study the effectiveness of medical treatments, each with their 
own benefits and challenges (Figure 1). Examples include the prospective longitudinal cohort 
study (of which a number of PD specific studies have emerged in the last few years, such as 
the Parkinson Progression Marker Initiative[26], the National Center of Excellence in 
Research–PD cohort[27] and the Parkinson Precision Project[28]), prognostic disease 
modeling,[29, 30] the randomized registry trial (i.e. combining a randomization procedure to 
already existing high-quality observational registries)[4] and the pragmatic RCT (where the 
basic concept is to combine the strength of randomization with the cost-savings of using 
administrative data for outcome ascertainment) [31]. Here, we will further focus on the 
analyses of medical claims data as an example of an alternative research method, 
complementary to the traditional RCT. 
 
ANALYSING MEDICAL CLAIMS TO STUDY PHYSIOTHERAPY FOR PARKINSON PATIENTS 
A recent study illustrates the value of this whole approach, in this specific case to 
demonstrate the cost-effectiveness of specialized physiotherapy.[3] There is now class II 
evidence to support the merits of specific physiotherapy interventions for patients with 
PD.[32] It is also clear that specific physiotherapy interventions such as external cueing 
require a great deal of PD-specific expertise to ascertain that these interventions are 
delivered optimally, i.e. both according to evidence-based guidelines[32] and tailored to 
each patient’s unique needs and personal profile. For example, inappropriate setting of 
visual or auditory cues is not only ineffective, but can lead to a worsening of gait disability in 
PD patients.[33, 34] Similar issues are at play when delivering other non-pharmacological 
interventions, such as occupational therapy, speech-language therapy or more recently 
introduced treatments such as cognitive rehabilitation or dance.[13] 
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To address this matter of PD-specific expertise, the ParkinsonNet model of care was 
introduced in 2004 in the Netherlands as an innovative treatment concept for patients with 
PD. Specifically, ParkinsonNet consists of regional community-based networks that 
encompass a number of dedicated allied health therapists who have been trained 
specifically according to evidence-based guidelines.[35] The core elements of the 
ParkinsonNet model include: (1) professional empowerment, by concentrating care among 
specifically trained professionals; (2) patient empowerment, by informing patients and 
including them as partners in healthcare; and (3) team empowerment, by organizing and 
supporting care into multidisciplinary, regional networks.[36] The professional training 
consists of a 4-day baseline course in PD according to evidence-based guidelines (for each 
discipline separately). Additionally, professionals are required to participate in regional 
meetings (thrice annually) and national congresses where the latest evidence is presented. 
ParkinsonNet has reached full national coverage in the Netherlands, and currently includes 
70 regional sub-networks with a total of 3,100 specifically trained healthcare professionals, 
including – among others – physiotherapists, occupational therapists, speech-langue 
therapists, dieticians, and Parkinson nurses.[16] 
 
The cost-effectiveness of this ParkinsonNet model has been studied in several RCTs, which 
overall revealed a better quality of care, lower healthcare costs and equal, if not better, 
health outcomes, at least in the short term (the longest follow-up was 6 months).[37-40] A 
recent review conservatively estimated the cost-savings to amount to at least 381 euros per 
patient annually,[36] and this would translate into an annual cost saving of around 15,2 
million euros for the entire Dutch population (around n=40,000 patients with PD). However, 
the aforementioned drawbacks of RCTs also applied here. Most importantly, there has been 
no information about the cost-effectiveness of specialized ParkinsonNet treatment in the 
long-term, within a representative real-life population. If the cost-effectiveness found in 
trials could be extrapolated to daily practice, then health insurers might have reasonable 
grounds to initiate a process of preferential or even selective reimbursement of 
ParkinsonNet therapy, thereby promoting better care and contributing to further cost 
savings. 
 
Stimulated by these considerations, one of the largest Dutch healthcare insurers (the CZ 
groep) took the initiative for a new evaluation of the ParkinsonNet model, using their own 
large medical claims database as their source of information.[3] The specific aim of this study 
was to compare the health outcomes and healthcare utilization of specialized physiotherapy 
via ParkinsonNet for a large, real-life population of people with PD, who had been followed 
for up for at least three years. Compared to RCTs, the inclusion criteria were purposely left 
broad: merely having a diagnosis of PD and being in receipt of physiotherapy as part of their 
regular PD care. Importantly, patients with co-morbid conditions were not excluded. Their 
claims database included a large group of no less than 4,381 patients who fulfilled these 
broad inclusion criteria. 
 
By chance, about half of these patients had received care by a specialized community-based 
ParkinsonNet physiotherapist (n=2,129 patients, with 4,649 observations over the 3-year 
period), while the other half had received usual care physiotherapy (n=2,252 patients, with 
5,353 observations). Importantly, this group separation did not result from careful 
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randomization, but was created by the fact that Dutch patients (and their referring 
physicians) are free to choose their physiotherapy providers. Theoretically, all sorts of bias 
could have affected this choice, but this is what happens in “real life”. Correcting for 
potential baseline differences was challenging because, as we pointed out earlier, a claims 
database does not contain any PD-specific information about disease duration or severity. 
The researchers tackled this issue by comparing the two groups for a number of reasonable 
proxies for PD-related health status: number of neurology outpatient visits, number of drugs 
for PD, presence of depression, use of mental healthcare, number of different consulted 
professionals, and number of co-morbid conditions. Their analyses identified only small and 
clinically irrelevant group differences, suggesting that at the least, both groups did not differ 
substantially with respect to their underlying PD. A final concern was socio-economic status, 
as patients with higher education might be more prone to seek treatment from a well-
trained expert. Therefore, socio-economic status was also corrected for in the statistical 
models and in addition showed to be very comparable between both groups. The results can 
neither be explained by differences in treatment intensity. In fact, the specialized 
ParkinsonNet therapists required significantly fewer treatment sessions than regular 
therapists, yet reached better outcomes. Finally, the investigators also took care to define a 
primary outcome prior to performing the analyses, and opted for the percentage of patients 
having one of the following common and major PD-related complications: hospital visits or 
admissions for sustaining a fracture, other orthopedic injuries, pneumonia, or a combination 
thereof. This outcome seems reasonable, because ParkinsonNet physiotherapists are 
specifically trained to promote safer mobility, by offering gait and balance training, reducing 
freezing of gait events, and thereby preventing falls and fall-related injuries.[35] 
 
The results were striking, showing that patients who had been treated by a specialized 
physiotherapist experienced significantly fewer PD-related complications (17.3%) compared 
to patients treated by a usual care physiotherapist (21.3%). Post-hoc analyses showed that 
this reduced risk of sustaining a complication was also significant for each of the three 
components of the primary outcome. It is likely that these outcomes can be ascribed to the 
specialized ParkinsonNet physiotherapy, as this was the only variable that consistently 
separated the two groups. An alternative option, that cannot be totally excluded, is that 
patients receiving specialized physiotherapy were also receiving specialized care by one or 
more of the other professional disciplines trained by ParkinsonNet.[16] For example, 
specialized speech-language therapists might have helped to reduce the risk of sustaining 
aspiration pneumonia, while home visits by specialized occupational therapists might have 
helped to remove domestic hazards for falls. Even though this was partially corrected for in 
the statistical model by including the number of healthcare professionals, the quality of 
these health professionals was not taken into account. To address this issue, further detailed 
analyses are now ongoing to identify which professional ParkinsonNet disciplines typically 
co-treat patients in daily practice. Such analyses would also help to further reinforce the 
quality of the multidisciplinary team approach for individual patients with PD, which is the 
ultimate goal of the ParkinsonNet approach. Nevertheless, if patients receiving specialized 
physiotherapy also incurred additional costs associated with provision of other specialist 
allied health services via ParkinsonNet, the positive cost-effectiveness outcomes of this 
study may be considered all the more impressive. 
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The investigators also analyzed whether the improved outcomes could be related to 
measures of better quality of care, and this was indeed the case. Specifically, the specialized 
physiotherapists treated a much higher case load (this helps to gain more expertise and 
‘practice makes perfect’)[41] and offered greater continuity of care than regular care 
therapists (which is greatly valued by patients). Moreover, specialized therapists required 
significantly fewer treatment sessions, which was expected since this is a part of their 
ParkinsonNet training (they are trained to support patients in self-management, and to 
utilize home-based and community-based exercise for maintaining gains made with 
supervised therapy),[35] whereas usual care therapists tend to offer chronic less intense 
maintenance treatments.[42] 
 
The better outcomes and greater quality of care also translated into tangible cost savings: 
compared to usual care physiotherapy, direct physiotherapy costs were almost €400 less 
annually for specialized therapy (reflecting their greater efficiency), while total healthcare 
costs (including hospital expenses) were on average €530 less annually (reflecting the 
prevented hospital visits). Finally, the investigators performed a very exploratory mortality 
analysis, motivated by the fact that survival in PD can be affected by specific complications 
such hip fractures or other fall-related injuries.[43-46] The uncorrected data showed a lower 
mortality risk for patients in the specialized physiotherapy group as compared to usual care 
(2.9% risk reduction), but this difference was no longer significant in a Cox’s proportional 
hazard model for survival time. 
 
SIGNIFICANCE AND FUTURE PERSPECTIVES 
The importance of this study lies, first of all, in the fact that this database claims analysis 
offered supporting evidence to confirm and extend the findings of prior RCTs, but now 
within a large and real-life population, and – importantly – over a much longer follow-up 
period (3 years). In contrast to the cluster-controlled trial performed in 2010,[37] the new 
claims analysis found better health outcomes (reduced percentage of patients having a 
complication) for patients treated by specialized physiotherapists. Several factors can 
explain this difference with the earlier 2010 study. First, the regional ParkinsonNet networks 
included in the new claims study were quite “mature” (i.e. they had been operational for 
several years, allowing the participating therapists to accrue additional PD-specific expertise 
from treating a high case load), while the networks in the 2010 study were newly founded 
and then immediately analyzed (i.e. the networks included freshly trained physiotherapists, 
without the additional expertise from years of daily clinical practice). Mature or seasoned 
therapist are likely to achieve better outcomes than freshly trained therapists.[16, 37]. 
Second, the 2010 study evaluated monodisciplinary networks that consisted of strictly 
physiotherapists. The new study evaluated regional networks that had meanwhile become 
multidisciplinary in nature.[16] As we mentioned earlier, we cannot fully exclude that 
patients who received specialized physiotherapy may also have received treatment by other 
specialized disciplines, and this may potentially have contributed to the positive outcomes, 
even though a correction for the number of other health professionals was applied. Finally, 
the follow-up duration of the RCT in 2010 was only 6 months,[37] which is hardly enough to 
measure clinically relevant changes in health status, and in particular for rare events such as 
fractures. In contrast, the new study had a much longer follow-up of 3 years.  
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 Both RCTs and claims analyses have their own strengths and weaknesses, and as such, the 
two approaches can really complement each other. Taking these two evidence sources 
together, it is now clear that, compared to generically trained professionals who treat PD 
patients only occasionally, specialized PD therapists offer better care, prevent major 
complications and hospital admissions, and help to reduce their treatment costs for society. 
These findings should stir a debate about promotion of evidence-based practice and 
specialization in the field of allied health, and indeed for many other health professionals 
delivering non-pharmacological interventions. In that regard, ParkinsonNet is just one 
example of how physiotherapy specialization in PD management can be achieved.  Some 
other countries provide opportunities specialization, for example, in Australia, specialist 
neurological physiotherapy training[47] includes PD, but is not limited to PD.  Whatever the 
process of specialization, a key fundamental is the need for high-level skills in evidence-
based practice, so that emerging evidence (not available in current guidelines and, where 
feasible, including evidence of cost-effectiveness) can be evaluated and implemented 
appropriately without delay. Recent examples include the PD-WEBB program (progressive 
strength and progressive balance exercises plus cueing strategies for freezing of gait) for falls 
prevention,[48]  and intensive amplitude training for improving writing.[49] 
 
Additionally, the recent study in The Lancet Neurology offers an interesting “proof of 
concept” for using medical claims (in countries where such systems of health care exist) as a 
new way of assessing healthcare interventions, and in particular complex treatments like 
specialized physiotherapy. The main lesson brought forward by this new paper is that 
medical claims databases contain a surprising wealth of information about relevant care 
issues in the field of PD, and that mining such databases can offer an inexpensive and 
attractive approach to learn more about the functioning of clinical interventions in a real-life 
setting. Linking medical claims databases to a clinical outcomes registry would also be in 
interesting option, as it would allow entry of more disease-specific outcomes into the 
analyses, and might help to address the issue of misclassification (by introducing a greater 
standardisation according to established criteria, for example using the recently published 
criteria for health outcomes).[50] Bearing in mind the drawbacks associated with claims 
analyses, the same approach could now be adopted with other healthcare disciplines, and 
even for a multidisciplinary team approach. In addition, this approach offers other unique 
opportunities, such as examining whether specialized interventions can help postpone 
admission to long-term care facilities such as nursing homes. Finally, other more invasive 
therapies for PD could also be tracked in similar ways, especially as we are entering an era of 
cell, gene and immune therapies. For example, do such therapies really impact on the 
problems of real life PD, and how do they compare with standards of care and non-
pharmacological therapies? The time is now fast approaching when we have to radically 
rethink how we assess what we do for patients, not in clinic, but in the real world. 
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Table 1. Studies that have used medical claims analyses in the field of PD. 
 
Study Database  Population Objective Results 
Ypinga et al. 
2017[3] 
Medical claims, 
CZ groep, 2013-
2015 
n=2129 patients 
with PD receiving 
specialised 
physiotherapy 
n=2252 patients 
with PD receiving 
usual care 
physiotherapy  
To study the long term 
benefits and costs of 
specialised physiotherapy 
using the ParkinsonNet 
approach  
Significantly fewer patients that 
received specialised 
physiotherapy had a PD related 
complication. Patients treated 
by a ParkinsonNet 
physiotherapist had significantly 
less physiotherapy costs ($456 
per patient per year) and total 
medical expenses ($612 per 
patient per year. Specialised 
physiotherapists used less 
physiotherapy sessions per 
patients, had a higher case-load 
of PD patients and a higher 
percentage of patients received 
care from the same 
physiotherapist 
Sierles-
Nielsen et al. 
2017[51] 
Medicare, 2004-
2009, United 
States 
66-90 years  
n=89,790 incident 
PD cases 
n=118,095 
controls 
To predict PD using 
demographic and medical 
claims data 
It is possible to identify people 
with a high probability of PD 
using diagnosis and procedure 
codes in the 5 years prior to PD 
diagnosis. This data is readily 
available in medical claims 
Fullard et al. 
2017[52] 
Medicare, 2007-
2009, United 
States 
 n= 174,643, 
patients with PD 
To study rehabilitations 
service utilization in 
patients with PD 
Outpatient rehabilitation 
utilization was low. In 2007:  
14.2% physiotherapy or 
occupational therapy, 14.6% 
speech therapy. 
Chou et al. 
2017[53] 
National Health 
Insurance 
Research 
Database, 1997-
2005 Taiwan 
n=1,944 patients 
diagnosed with 
sleep apnea n= 
9,720 matched 
controls without 
sleep apnea 
To study the risk of PD 
following a diagnosis with 
sleep apnea using a 3-year 
follow-up period 
17 (0.9%) patients with sleep 
apnea and 38 (0.4%) controls 
were diagnosed with PD during 
follow-up. Patients with sleep 
apnea had a 1.85-fold higher risk 
of PD than controls  
Yang et al. 
2017[54] 
National Health 
Insurance 
Research 
Database, 2000-
2011, Taiwan 
n=36,294 patients 
newly diagnosed 
with Diabetes 
Mellitus in 2000-
2006 
n=108,882 healthy 
controls  
To study the risk of PD 
following a diagnosis of 
Diabetes Mellitus (follow-
up until 2011). 
The risk of PD was 1.36-fold 
higher in the patients with 
Diabetes Mellitus compared to 
the healthy controls.  
Huang et al. 
2016[55] 
National Health 
Insurance 
Research 
Database, 2008-
2012, Taiwan 
n= 6455 patients 
with PD receiving 
major surgery in 
2008-2012. 
n=12,910 controls 
To study the risk of post-
operative complications 
and mortality after non-
neurological surgery in PD 
patients  
Patients with PD had an 
increased risk of postoperative 
pulmonary embolism, stroke, 
pneumonia, urinary tract 
infection, septicemia, acute 
renal failure, and mortality 
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Crispo et al. 
2016[56] 
 
Cerner Health 
Facts® database 
N= 16,302 PD 
hospitalized 
patients 
hospitalized  
To study anticholinergic 
medication use, 
diagnoses, and hospital 
readmission 
More than half of hospitalized 
PD were prescribed medications 
with moderate to very strong 
anticholinergic potential. 
Anticholinergic medication use 
was associated with increased 
odds of ED visits and 30 day 
readmission  
Kwak, 
2015[57] 
National Health 
Insurance 
Research 
Database, 2013, 
Taiwan 
n=4,137 patients 
with PD 
To study the social 
demographic 
characteristics and health 
service use of patients 
with PD in Korea 
The prevalence of PD was 3.54 in 
1,000 in 2013. On average 9.83 
outpatient visit days and 25.3 
inpatient hospitalization days 
were found. Annual direct 
medical costs were USD 487 for 
an outpatient and USD 10,429 
for an inpatient. 
Chen et al. 
2015[58] 
National Health 
Insurance 
Research 
Database, 2000-
2009, Taiwan 
n=5864 patients 
with newly 
diagnosed 
obstructive sleep 
apnea  
n=23,269 controls 
To study the risk of PD in 
patients with obstructive 
sleep apnea 
The incidence of PD was 
approximately two times higher 
for patients with sleep apnea 
with an adjusted hazard ratio of 
1.84.  
Huang et al. 
2015[59] 
National Health 
Insurance 
Research 
Database, 2000-
2003, Taiwan 
n=1,423 patients 
with PD 
n= 5,692 controls 
Followed-up until 
2008 
This study the risk of 
fractures and post-
fracture outcomes in 
patients with PD. 
Patients with PD had a higher 
risk of fractures and 
complications following 
fractures than controls  
Benzinger et 
al. 2014[60] 
Database from a 
German health 
insurance 
company, 2004-
2008. 
n=23,469 patients 
with ‘possible PD’ 
n=12,391 patients 
with ‘probably PD’ 
n=860,388 
reference group 
To study the risk of 
femoral fracture in 
patients with PD 
Patients with PD had a more 
than doubled risk of a femoral 
fracture 
Wang et al. 
2014[61] 
National Health 
Insurance 
Research 
Database, 1997-
2010, Taiwan 
n=8,325 patients 
with end-stage 
renal disease 
n=33,382 controls  
To study the risk of PD in 
patients with end stage 
renal disease 
The risk of PD was 1.55-fold 
higher in patients with end stage 
renal disease compared to 
controls 
Harris-Hayes 
et al. 
2014[45] 
Medicare, 2000-
2005, United 
States  
n=1,980,401 
people with a hip 
or pelvic fracture, 
of which n= 
131,215 with PD 
To study mortality 
associated with 
demographic factors after 
hip or pelvic fracture in 
patients with PD.  
The adjusted mortality rate after 
hip/pelvic fracture in individuals 
with PD was higher than in those 
without PD 
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Lai et al. 
2014[62] 
National Health 
Insurance 
Research 
Database, 2000-
2010, Taiwan 
n= 4,976 patients 
with hearing loss 
n=19,904 controls 
To study the risk of PD in 
patients with hearing loss 
The risk of PD was higher in 
patients with hearing loss than 
in controls  
Suh et al. 
2012[63]  
Medstat 
MarketScan® 
Claims and 
Encounters 
research 
database, 2004-
2008, United 
States 
n=1,312 patients 
with PD and 
levodopa-induced 
dyskinesias 
n=1,312 patients 
with a 
prescription for 
levodopa and a 
primary or 
secondary 
diagnosis of PD, 
without levodopa-
induced 
dyskinesias 
To study the treatment 
patterns, direct 
healthcare costs and 
predictors of treatment 
costs associated with 
levodopa-induced 
dyskinesia in PD 
Total treatment costs increased 
from $18,645 to $26,439 (from 
12 months preceding levodopa-
induced dyskinesia to 12 months 
after onset). PD-related costs 
increased from $3917 to $8110. 
Hobson et al. 
2012[64] 
Administrative 
data from 
Manitoba, 
Canada 
n=1,469 patients 
with PD 
n=2,938 controls 
To study healthcare 
utilization and the factors 
associated with 
healthcare utilization and 
prescription drug use for 
patients with PD (6-year 
follow-up) 
Patients with PD had greater 
healthcare utilization than 
controls (except for visits to non-
neurological specialists and 
hospital use for non-mental 
disorder diagnoses). 
Ooba et al. 
2011[65] 
Vendor, medical 
claims database, 
2005-2008, 
Japan 
n=574 patients 
with PD 
To study the impact of 
regulatory actions (e.g. 
requiring physicians to 
perform periodic 
ultrasonic cardiography in 
patients who take 
cabergoline or pergolide) 
on prescribing dopamine 
receptor agonists  
No decrease in the proportion of 
patients prescribed cabergoline 
or pergolide was found. 
Prescription tended to increase 
Davis et al. 
2010[66] 
Insurance claims 
from 30 health 
plans, 1997-
2004, United 
States  
n=3,119 patients 
with PD 
To study the prevalence 
of medication 
nonadherence and its 
association with 
healthcare costs 
61% of the PD patients were 
non-adherent. Higher healthcare 
costs were found for non-
adherent patients compared to 
adherent patients.  
Safarpour D 
et al 2015[67] 
 
Insurance claims 
from Medicare 
program, United 
States 2002-
2006 
N= 469,055 
individuals with 
PD 
To study long term care 
facility (LTCF) and hospice 
use in PD patients 
25% of PD patients resided in a 
long-term care facility. Hip 
fracture and dementia were 
associated with LTCF use.  LTCF 
PD patients infrequently 
received neurologist care. 
Willis AW et 
al. 2014[68] 
Insurance claims 
from Medicare 
program, United 
N=657,000 
Medicare 
To study 
sociodemographic, 
clinical, and 
DBS was infrequently used. Non-
white and female PD patients 
were less likely to receive DBS. 
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 States 2002-
2005 
beneficiaries with 
PD 
physician/practice factors 
associated with deep 
brain stimulation (DBS). 
Beneficiaries treated in diverse 
physician practices were less 
likely to receive DBS, regardless 
of individual race  
Willis Aw et 
al 2013[69] 
Insurance claims 
from Medicare 
program, United 
States, 2005 
14,354 PD 
patients aged 30-
64 who receive 
Medicare benefits 
by virtue of being 
disabled 
To study the 
characteristics of the 
Young disabled PD 
population in the United 
States and to quantify the 
burden of 
neuropsychiatric disease 
manifestations in this 
group. 
The race and sex distribution of 
Young disabled PD patients was 
similar to that seen in the 
general population: 
White>nonwhite, male>female.  
Young PD patients more often 
were diagnosed with depression, 
dementia, substance abuse, 
psychosis, and impulse control 
disorders 
Willis AW et 
al 2012[70] 
Insurance claims 
from Medicare 
program, United 
States, 2002-
2006 
N=24,929 incident 
PD cases 
To investigate the impact 
of neurologist care on 
Parkinson disease (PD)-
related hospitalizations in 
the United States 
Neurologist PD care was 
associated with lower adjusted 
odds of both initial and repeat 
hospitalization for psychosis, 
urinary tract infection and 
traumatic injury. Odds of general 
illness hospitalization or 
hospitalization did not differ by 
neurologist involvement. 
Willis, AW et 
al 2012[71] 
 
Insurance claims 
from Medicare 
program, United 
States, 2002-
2008 
N= >138 000 
Medicare 
beneficiaries ages 
65+ with incident 
PD 
To determine survival for 
older patients with 
Parkinson disease (PD) in 
the United States  
Thirty-five percent of patients 
with PD lived more than 6 years. 
Female, Hispanic, Asian patients 
had a lower adjusted risk of 
death than white men. 
Willis AW et 
al 2011[72] 
Insurance claims 
from Medicare 
program, United 
States, 2002-
2005 
N= >138 000 
Medicare 
beneficiaries ages 
65+ with incident 
PD 
To study the utilization of 
neurologist providers in 
the treatment of patients 
with Parkinson disease 
(PD) in the United States 
and determine whether 
neurologist treatment is 
associated with improved 
clinical outcomes. 
Only 58% of patients with PD 
received neurologist care 
between 2002 and 2005.  
Women and minorities were less 
likely to be treated by a 
neurologist 
Weintraub, D 
et al. 2017 
[73] 
 
Veterans Health 
Administration 
data (1999-
2010) 
6,679 matched PD 
pairs 
To determine if 
antipsychotic (AP) use in 
Parkinson disease (PD) 
patients is associated with 
increased physical 
morbidity 
AP is associated with 
significantly increased ED, 
inpatient, and outpatient visits 
and mortality in PD patients 
Makaroff et 
al. 2011[74] 
PharMetrics 
Patient- 
Centric 
Database, 2000-
2008 Unites 
States  
N= 5,579 patients 
with a 
prescription for 
levodopa and/ or 
dopamine agonist 
To study the incidence of 
gastrointestinal disorders 
in PD patients and to 
examine subsequent PD-
related outcomes 
Incidence of gastrointestinal 
disorders increased over time to 
65% at four years after PD 
diagnosis. Patients with 
gastrointestinal disorders had 
higher rates of psychosexual 
dysfunction, anxiety, depression, 
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ataxia, pain, movement 
disorders, urinary incontinence 
and falls.  
Guttman et 
al. 2001[75] 
Health 
insurance 
data,1993-1998, 
Canada 
N=15,304 patients 
with parkinsonism 
N=30,608 controls 
To study mortality rate in 
patients receiving 
treatment for 
parkinsonism 
Cases with parkinsonism had a 
higher risk of mortality with an 
overall mortality odds ratio of 
2.5 (95% CI: 2.4, 2.6) compared 
with the control group 
Chan et al. 
2014[76] 
The Nationwide 
Inpatient 
Sample and 
Area Resource 
File,2002-2009, 
United States 
2,408,302 PD 
discharges 
18,312 PD 
discharges for DBS 
 
To study the use of deep 
brain stimulation in PD 
and to determine the 
factors that drive DBS use 
in the Unites States   
Predictors for DBS use included 
younger age, male sex, 
increasing income quartile of 
patient zip code, large hospitals, 
teaching hospitals, urban 
setting, hospitals with higher 
number of annual discharges for 
PD, and increased countywide 
density of neurologists 
Predictors of nonuse included 
African American race, Medicaid 
use, and increasing comorbidity 
score  
Dahodwala et 
al. 2009[77] 
Pennsylvania 
State Medical 
Claims, United 
States 
N=307 incident PD 
cases 
To identify racial 
disparities in the 
treatment of PD 
African-Americans were four 
times less likely than whites to 
receive any PD treatment, 
especially indicated medications. 
Noyes et al. 
2006[78] 
Medicare 
Current 
Beneficiary 
Survey, 1992-
2000, United 
States 
N=35,217 
Medicare 
beneficiaries ≥65 
years old 
N=717 PD patients  
To evaluate medical 
utilization and economic 
burden of self-reported 
PD on patients and 
society 
PD patients used significantly 
more health care services paid 
significantly more out of pocket 
for their medical services than 
controls. PD patients also had 
higher annual health care and 
were more likely to use medical 
care, in particular for long-term 
care and home health care 
Lapane et al. 
1999[79] 
Medicare, 1992-
1996, United 
States 
N=470.000 
residents of long 
term care facilities 
N=24,402 nursing 
home residents 
with a diagnosis of 
PD  
To stud the epidemiology 
of PD in long term care 
facilities  
The prevalence of PD in nursing 
homes was 5.2%, with peak age-
specific prevalence between 
ages 75 and 84 years. 70% had 
cognitive impairments, and over 
80% had functional disability. 
Less than 10% had verbal and 
physical signs of grief and 
anxiety, and 80% exhibited poor 
psychosocial well-being. Only 
44% received antiparkinsonian 
drugs. 
 
Search terms: Parkinson’s disease AND medical claims OR administrative data, November 21th 2017, 42 hits  
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